20,521 Shares in Stoke Therapeutics, Inc. $STOK Bought by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 20,521 shares of the company’s stock, valued at approximately $686,000.

Other institutional investors have also recently made changes to their positions in the company. RTW Investments LP raised its position in shares of Stoke Therapeutics by 8.3% during the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after acquiring an additional 423,331 shares during the last quarter. Morgan Stanley boosted its holdings in Stoke Therapeutics by 0.3% in the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after acquiring an additional 9,108 shares during the last quarter. State Street Corp increased its position in Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after purchasing an additional 1,072,176 shares during the period. BVF Inc. IL increased its position in Stoke Therapeutics by 36.7% during the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock valued at $71,912,000 after purchasing an additional 608,578 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after purchasing an additional 293,072 shares during the last quarter.

Analyst Ratings Changes

STOK has been the topic of a number of recent analyst reports. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. The Goldman Sachs Group initiated coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They set a “buy” rating and a $44.00 price objective for the company. Finally, Weiss Ratings lowered shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.00.

Stoke Therapeutics Stock Performance

Shares of STOK stock opened at $30.04 on Friday. The company has a market cap of $1.87 billion, a P/E ratio of -10.69 and a beta of 1.17. The stock has a 50 day simple moving average of $30.39 and a two-hundred day simple moving average of $32.01. Stoke Therapeutics, Inc. has a fifty-two week low of $12.40 and a fifty-two week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. The firm had revenue of $6.23 million for the quarter, compared to analysts’ expectations of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. On average, research analysts predict that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares in the company, valued at approximately $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the sale, the general counsel directly owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. This trade represents a 7.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by insiders.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.